Immunic, Inc. does not pay cash dividends to its common shareholders, adhering to a capital allocation strategy standard for clinical-stage and emerging biopharmaceutical enterprises. The company directs all available financial resources toward funding extensive late-stage clinical trials, laboratory research, regulatory compliance frameworks, and operational infrastructure required to advance its therapeutic pipeline toward commercialization. Investors acquiring shares in the company look exclusively toward potential long-term capital appreciation driven by successful clinical readouts, regulatory approvals, and corporate growth rather than periodic income generation through dividends.